Jennifer L Sauter

List of Publications by Year
in descending order

39 papers	5,844 citations	279701 23 h-index	345118 36 g-index
40 all docs	40 docs citations	40 times ranked	8245 citing authors

#	Article	IF	Citations
1	Molecular Determinants of Response to Antiâ€“Programmed Cell Death (PD)-1 and Antiâ€“Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Nonâ€“Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. Journal of Clinical Oncology, 2018, 36, 633-641.	0.8	1,109
2	STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discovery, 2018, 8, 822-835.	7.7	1,108
3	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell, 2018, 33, 843-852.e4.	7.7	827
4	PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. Journal of Thoracic Oncology, 2018, 13, 1302-1311.	0.5	589
5	SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization. Journal of Thoracic Oncology, 2020, 15, 1823-1835.	0.5	234
6	Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Nonâ€“Small Cell Lung Cancer. Cancer Research, 2019, 79, 1214-1225.	0.4	226
7	A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Antiâ€“PD-1 Agent Pembrolizumab. Cancer Discovery, 2021, 11, 2748-2763.	7.7	222
8	SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas. Journal of Thoracic Oncology, 2020, 15, 231-247.	0.5	172
9	SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior. Modern Pathology, 2017, 30, 1422-1432.	2.9	135
10	The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer. Clinical Cancer Research, 2020, 26, 5701-5708.	3.2	133
11	Validation of a digital pathology system including remote review during the COVID-19 pandemic. Modern Pathology, 2020, 33, 2115-2127.	2.9	112
12	EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. Journal of Thoracic Oncology, 2020, 15, 29-49.	0.5	106
13	Insights into pathogenesis of fatal COVIDâ€19 pneumonia from histopathology with immunohistochemical and viral RNA studies. Histopathology, 2020, 77, 915-925.	1.6	92
14	Bronchiolar Adenoma. American Journal of Surgical Pathology, 2018, 42, 1010-1026.	2.1	91
15	Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. Clinical Cancer Research, 2020, 26, 2849-2858.	3.2	74
16	Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study. Modern Pathology, 2018, 31, 598-606.	2.9	70
17	Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach. Clinical Cancer Research, 2019, 25, 7113-7125.	3.2	69
18	V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma. Modern Pathology, 2020, 33, 303-311.	2.9	65

#	Article	IF	Citations
19	The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification. Journal of Thoracic Oncology, 2022, 17, 608-622.	0.5	64
20	Young investigator challenge: Validation and optimization of immunohistochemistry protocols for use on cellient cell block specimens. Cancer Cytopathology, 2016, 124, 89-100.	1.4	63
21	Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center. Journal of Thoracic Oncology, 2020, 15, 1037-1053.	0.5	40
22	Results from the 2019 American Society of Cytopathology survey on rapid on-site evaluationâ€"Part 1: objective practice patterns. Journal of the American Society of Cytopathology, 2019, 8, 333-341.	0.2	30
23	Identification of Immunohistochemical Reagents for In Situ Protein Expression Analysis of Coronavirus-associated Changes in Human Tissues. Applied Immunohistochemistry and Molecular Morphology, 2021, 29, 5-12.	0.6	26
24	Expanding the spectrum of pulmonary histopathological manifestations of antiâ€synthetase syndrome: antiâ€EJâ€associated acute fibrinous and organizing pneumonia. Histopathology, 2014, 65, 581-582.	1.6	24
25	Assessment of The Bethesda System for Reporting Thyroid Cytopathology. American Journal of Clinical Pathology, 2019, 152, 502-511.	0.4	24
26	Molecular Characterization of Peritoneal Mesotheliomas. Journal of Thoracic Oncology, 2022, 17, 455-460.	0.5	24
27	The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study. The Lancet Digital Health, 2021, 3, e565-e576.	5.9	23
28	Testing of Integrated Human Papillomavirus mRNA Decreases Colposcopy Referrals: Could a Change in Human Papillomavirus Detection Methodology Lead to More Cost-Effective Patient Care?. Acta Cytologica, 2014, 58, 162-166.	0.7	18
29	Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung Cancer. Clinical Cancer Research, 2022, 28, 3797-3803.	3.2	15
30	Results from the 2019 American Society ofÂCytopathology survey on rapid onsite evaluation (ROSE)â€"part 2: subjective views among the cytopathology community. Journal of the American Society of Cytopathology, 2020, 9, 570-578.	0.2	11
31	Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations. Journal of Thoracic Oncology, 2019, 14, 1989-1994.	0.5	10
32	Displaced Cartilage Within Lymph Node Parenchyma Is a Novel Biopsy Site Change in Resected Mediastinal Lymph Nodes Following EBUS-TBNA. American Journal of Surgical Pathology, 2019, 43, 497-503.	2.1	10
33	Increased utilization, verification, and clinical implications of immunocytochemistry: Experience in a northern <scp>N</scp>ew <scp>E</scp>ngland hospital. Diagnostic Cytopathology, 2015, 43, 688-695.	0.5	9
34	Co-existence of Sarcina Organisms and Helicobacter pylori Gastritis/Duodenitis in Pediatric Siblings. Journal of Clinical & Anatomic Pathology (JCAP), 2013, 1, .	0.4	8
35	Pathological findings in spontaneous pneumothorax specimens: does the incidence of unexpected clinically significant findings justify routine histological examination?. Histopathology, 2015, 66, 675-684.	1.6	6
36	Immune checkpoint inhibitorâ€related pneumonitis: Acute lung injury with rapid progression and organizing pneumonia with less severe clinical disease. Histopathology, 0, , .	1.6	4

#	Article	IF	Citations
37	Type A thymoma presenting with bone metastasis. Histopathology, 2018, 73, 701-703.	1.6	1
38	Have the 2006 <scp>A</scp>merican Society for Colposcopy and Cervical Pathology (ASCCP) Guidelines Enriched the Yield of Highâ€Grade Squamous Intraepithelial lesions?. Diagnostic Cytopathology, 2015, 43, 673-675.	0.5	0
39	In Reply. Journal of Thoracic Oncology, 2020, 15, e94-e95.	0.5	0